Formycon AG has entered into an exclusive licensing and supply agreement with Zydus Lifesciences Limited for FYB206, a biosimilar to Keytruda®, in the U.S. and Canada.

Target Information

Formycon AG is a prominent developer of high-quality biosimilars, focused on biopharmaceuticals that treat various serious conditions. The company has established its reputation by concentrating on fields such as ophthalmology, immunology, and oncological therapies, backed by a comprehensive approach that spans technical development all the way through the regulatory approval process. Formycon has already successfully launched biosimilars like FYB201/ranibizumab and FYB202/ustekinumab, and is progressing with pipeline candidates, enhancing patient access to effective treatment.

In a significant development, Formycon has partnered with Zydus Lifesciences Limited to secure an exclusive licensing and supply agreement for FYB206, a biosimilar to Keytruda® (pembrolizumab), targeted at the U.S. and Canadian markets. This agreement leverages Formycon's extensive expertise in biosimilars and Zydus' commercial capabilities, setting the stage for a robust introduction in North America.

Industry Overview

The biosimilars market has been experiencing rapid growth, driven by an increasing recognition of their potential to reduce healthcare costs while maintaining patient access to effective therapies. In th